China Securities Intelligent Financial News Haimu Star (688559) announced on the evening of May 20 that the company has recently made a major breakthrough in key technologies and medical applications of mid-infrared femtosecond laser (the mid-infrared with a wavelength exceeding 5μm is called long-wave infrared in China).
As of the announcement disclosure date, the company has successfully developed a long-wave infrared continuously tunable benchtop femtosecond laser (LWIRFS). The laser has a tuning range of 5-11 m, a maximum output power of>1 W, a maximum pulse energy of>2 J, and a pulse width of <300 fs., the repetition frequency is 500 kHz. This research and development achievement is a pioneering product in the world, and there is currently no benchmark product in the world.
The announcement shows that the company entrusted the Sichuan Province Science and Technology Collaborative Innovation Promotion Association to organize industry experts in Chengdu to review the scientific and technological achievements of the company's completion of the "High Power Broadband Tunable Long Wave Infrared Femtosecond Laser System" project, and also entrusted the Southwest Information Center of the Ministry of Science and Technology and CNAS Third-party authoritative review agencies such as the China National Accreditation Commission for Conformity Assessment have conducted scientific and technological achievement appraisal, academic achievement (appraisal) domestic and foreign novelty research and product measurement on the company's scientific and technological research results, academic achievements and products of this product, and Relevant authoritative reports have been issued recently.
The announcement stated that the company's major breakthroughs in mid-infrared femtosecond laser technology and key technologies in medical applications fully reflect the company's independent research and development and continuous innovation capabilities, and provide the company's layout in the fields of medical lasers, medical health and medical beauty. Provide strong technical guarantee.
The company will rely on the continuous innovation of this technology to complete clinical trials of relevant medical device products as soon as possible, and obtain Class II and Class III medical licenses for relevant products. After obtaining Class II and Class III medical licenses for relevant medical device products, the company strives to achieve the industrialization layout and large-scale production of medical-related industries within three to five years, and gradually promote the industrialization process.
(Article sourcepennbattle33000reel: China Securities Journal·China Securities Network)
